Logo image of HIVE.CA

HIVE DIGITAL TECHNOLOGIES LT (HIVE.CA) Stock Fundamental Analysis

TSX-V:HIVE - TSX Venture Exchange - CA4339211035 - Common Stock - Currency: CAD

2.435  -0.04 (-1.81%)

Fundamental Rating

4

HIVE gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 63 industry peers in the Software industry. HIVE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HIVE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

HIVE had negative earnings in the past year.
In the past year HIVE has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: HIVE reported negative net income in multiple years.
HIVE had a positive operating cash flow in each of the past 5 years.
HIVE.CA Yearly Net Income VS EBIT VS OCF VS FCFHIVE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -1.38%, HIVE is in line with its industry, outperforming 52.38% of the companies in the same industry.
The Return On Equity of HIVE (-1.52%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -1.38%
ROE -1.52%
ROIC N/A
ROA(3y)-39.86%
ROA(5y)-22.35%
ROE(3y)-52.71%
ROE(5y)-29.43%
ROIC(3y)N/A
ROIC(5y)N/A
HIVE.CA Yearly ROA, ROE, ROICHIVE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

HIVE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HIVE.CA Yearly Profit, Operating, Gross MarginsHIVE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

HIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HIVE has been increased compared to 1 year ago.
The number of shares outstanding for HIVE has been increased compared to 5 years ago.
The debt/assets ratio for HIVE has been reduced compared to a year ago.
HIVE.CA Yearly Shares OutstandingHIVE.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
HIVE.CA Yearly Total Debt VS Total AssetsHIVE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 4.02 indicates that HIVE is not in any danger for bankruptcy at the moment.
HIVE's Altman-Z score of 4.02 is fine compared to the rest of the industry. HIVE outperforms 69.84% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that HIVE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.04, HIVE is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 4.02
ROIC/WACCN/A
WACC9.75%
HIVE.CA Yearly LT Debt VS Equity VS FCFHIVE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

HIVE has a Current Ratio of 10.41. This indicates that HIVE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 10.41, HIVE belongs to the top of the industry, outperforming 93.65% of the companies in the same industry.
HIVE has a Quick Ratio of 10.41. This indicates that HIVE is financially healthy and has no problem in meeting its short term obligations.
HIVE has a better Quick ratio (10.41) than 93.65% of its industry peers.
Industry RankSector Rank
Current Ratio 10.41
Quick Ratio 10.41
HIVE.CA Yearly Current Assets VS Current LiabilitesHIVE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.45% over the past year.
The Revenue has grown by 26.29% in the past year. This is a very strong growth!
HIVE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.18% yearly.
EPS 1Y (TTM)95.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)26.29%
Revenue growth 3Y19.73%
Revenue growth 5Y29.18%
Sales Q2Q%-6.47%

3.2 Future

The Earnings Per Share is expected to grow by 41.15% on average over the next years. This is a very strong growth
HIVE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.54% yearly.
EPS Next Y69.3%
EPS Next 2Y43.28%
EPS Next 3Y41.15%
EPS Next 5YN/A
Revenue Next Year2.92%
Revenue Next 2Y64.95%
Revenue Next 3Y65.98%
Revenue Next 5Y42.54%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HIVE.CA Yearly Revenue VS EstimatesHIVE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
HIVE.CA Yearly EPS VS EstimatesHIVE.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

HIVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 65.99, HIVE can be considered very expensive at the moment.
65.08% of the companies in the same industry are more expensive than HIVE, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of HIVE to the average of the S&P500 Index (22.30), we can say HIVE is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 65.99
HIVE.CA Price Earnings VS Forward Price EarningsHIVE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -18.21
HIVE.CA Per share dataHIVE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HIVE's earnings are expected to grow with 41.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.28%
EPS Next 3Y41.15%

More info and screens

0

5. Dividend

5.1 Amount

HIVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HIVE DIGITAL TECHNOLOGIES LT

TSX-V:HIVE (6/2/2025, 7:00:00 PM)

2.435

-0.04 (-1.81%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)06-23 2025-06-23/bmo
Inst Owners23.92%
Inst Owner ChangeN/A
Ins Owners0.42%
Ins Owner ChangeN/A
Market Cap440.44M
Analysts80
Price Target7.14 (193.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.43%
Min EPS beat(2)43.42%
Max EPS beat(2)109.43%
EPS beat(4)4
Avg EPS beat(4)73.63%
Min EPS beat(4)43.42%
Max EPS beat(4)109.43%
EPS beat(8)6
Avg EPS beat(8)43.71%
EPS beat(12)7
Avg EPS beat(12)-161.22%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.98%
Min Revenue beat(2)-8.08%
Max Revenue beat(2)6.13%
Revenue beat(4)3
Avg Revenue beat(4)5.1%
Min Revenue beat(4)-8.08%
Max Revenue beat(4)17.08%
Revenue beat(8)6
Avg Revenue beat(8)4.45%
Revenue beat(12)9
Avg Revenue beat(12)18.22%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-37.5%
EPS NY rev (1m)0%
EPS NY rev (3m)26.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 65.99
P/S 2.66
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA -18.21
EPS(TTM)-0.04
EYN/A
EPS(NY)0.04
Fwd EY1.52%
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.92
BVpS3.29
TBVpS3.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.38%
ROE -1.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.86%
ROA(5y)-22.35%
ROE(3y)-52.71%
ROE(5y)-29.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA 1.22
Cap/Depr 126.51%
Cap/Sales 68.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.41
Quick Ratio 10.41
Altman-Z 4.02
F-Score3
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)132.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.57%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y69.3%
EPS Next 2Y43.28%
EPS Next 3Y41.15%
EPS Next 5YN/A
Revenue 1Y (TTM)26.29%
Revenue growth 3Y19.73%
Revenue growth 5Y29.18%
Sales Q2Q%-6.47%
Revenue Next Year2.92%
Revenue Next 2Y64.95%
Revenue Next 3Y65.98%
Revenue Next 5Y42.54%
EBIT growth 1Y-12.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year181.18%
EBIT Next 3Y78.28%
EBIT Next 5Y52.68%
FCF growth 1Y-59.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-169.13%
OCF growth 3Y-17.04%
OCF growth 5YN/A